Prophylactic Effect of Rebamipide on Aspirin-Induced Gastric Lesions and Disruption of Tight Junctional Protein Zonula Occludens-1 Distribution-Reference-Cited by-同舟云学术

Prophylactic Effect of Rebamipide on Aspirin-Induced Gastric Lesions and Disruption of Tight Junctional Protein Zonula Occludens-1 Distribution

Published:2008 Issue:3 Volume:106 Page:469-477
ISSN:1347-8613
Container-title:Journal of Pharmacological Sciences
language:en
Short-container-title:J Pharmacol Sci

Author:

Suzuki Takahiro,Yoshida Norimasa,Nakabe Nami,Isozaki Yutaka,Kajikawa Hirokazu,Takagi Tomohisa,Handa Osamu,Kokura Satoshi,Ichikawa Hiroshi,Naito Yuji,Matsui Hirofumi,Yoshikawa Toshikazu

Publisher

Japanese Pharmacological Society

Subject

Pharmacology,Molecular Medicine

Reference68 articles.

1. 1 [No authors listed]. Collaborative overview of randomized trials of antiplatelet therapy – I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists’ Collaboration. BMJ. 1994;308:81–106.

2. 2 Antithrombotic Trialists’ Collaboration: Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324:71–86.

3. 3 Patrono C, Garcia Rodriguez LA, Landolfi R, Baigent C. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med. 2005;353:2373–2383.

4. 4 Sorensen HT, Mellemkjaer L, Blot WJ, Nielsen GL, Steffensen FH, McLaughlin JK, et al. Risk of upper gastrointestinal bleeding associated with use of low-dose aspirin. Am J Gastroenterol. 2000;95:2218–2224.

5. 5 Derry S, Loke YK. Risk of gastrointestinal haemorrhage with long term use of aspirin: meta-analysis. BMJ. 2000;321:1183–1187.

Cited by 41 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Gastrointestinal disorders in post-COVID syndrome. Clinical guidelines;Experimental and Clinical Gastroenterology;2023-05-20

2. Syndrome of increased epithelial permeability: opportunities of current pharmacotherapy;Experimental and Clinical Gastroenterology;2023-01-18

3. Pharmacokinetics and pharmacodynamics of rebamipide. New possibilities of therapy: A review;Terapevticheskii arkhiv;2023-01-16

4. Evaluation of the effi cacy of rebamipide in functional dyspepsia and irritable bowel syndrome treatment;Experimental and Clinical Gastroenterology;2022-10-07

5. Combinational Approaches Targeting Various Aspects Involved in Intestinal Barrier Dysfunction-Induced Anxiety;Current Drug Targets;2022-08